Core Viewpoint - Yifan Pharmaceutical (002019) emphasizes its commitment to sustainable development, focusing on environmental protection, social responsibility, and corporate governance [1] Group 1 - The company has consistently prioritized sustainable development [1] - The company values environmental protection as part of its operational strategy [1] - The company is dedicated to fulfilling its social responsibilities [1]

Core Viewpoint - Yifan Pharmaceutical (002019) remains focused on its core business development and reports that operations are running smoothly, with management expressing confidence in future growth [1] Company Summary - The company is actively engaging with investors through interactive platforms, indicating a commitment to transparency and communication [1] - Management's confidence suggests a positive outlook for the company's strategic direction and operational performance [1]

Core Viewpoint - Recently, there have been no on-site research activities conducted by institutional investors for Yifan Pharmaceutical (002019.SZ) [1] Company Summary - Yifan Pharmaceutical confirmed on October 22 that there have been no recent on-site research activities by institutional investors [1]

Core Viewpoint - The company has not yet received feedback from its exclusive U.S. distributor regarding the sales performance of F627 in the third quarter [1] Group 1 - An investor inquired about the sales situation of F627 in the U.S. and whether it met or exceeded expectations [1] - The company expressed gratitude for the inquiry and confirmed the lack of feedback from its partner [1]

www.leadleo.com 2025年中国皮肤抗真菌中成药行业短报告： 止癣寻求天然的答案 Topical Antifungal Chinese Patent Medicine Industry 中国皮膚抗真菌漢方薬業界 概览标签：皮肤科、抗真菌、中成药 主笔人：钟琪 1 ©2025 LeadLeo 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均 系头豹研究院独有的高度机密性文件（在报告中另行标明出处者除外 ）。 ，任何人不得以任何方式擅自复制 、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述 约定的行为发生，头豹研究院保留采取法律措施，追究相关人员责任 的权利。头豹研究院开展的所有商业活动均使用"头豹研究院"或"头豹 "的商号、商标，头豹研究院无任何前述名称之外的其他分支机构， 也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 www.leadleo.com 400-072-5588 #6C0000 #7C0000 #940000 #B20000 #C00000 #E00000 #E994A6 #F3C3CD 标准色 #9A0000 衍生色 #D4C4C4 #BFBFB ...

Core Viewpoint - Yifan Pharmaceutical's stock has shown a year-to-date increase of 31.64%, with recent fluctuations indicating a slight decline over the past 20 and 60 days, suggesting potential volatility in the near term [1][2]. Financial Performance - For the first half of 2025, Yifan Pharmaceutical reported a revenue of 2.635 billion yuan, reflecting a year-on-year growth of 0.11%, while the net profit attributable to shareholders was 304 million yuan, marking a significant increase of 19.91% [2]. - Cumulatively, since its A-share listing, Yifan Pharmaceutical has distributed a total of 1.328 billion yuan in dividends, with 243 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yifan Pharmaceutical stood at 46,600, a decrease of 0.46% from the previous period, while the average number of circulating shares per person increased by 0.46% to 18,048 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 25.5819 million shares, which is an increase of 2.4783 million shares compared to the previous period [3]. Stock Performance - As of October 15, Yifan Pharmaceutical's stock price was 13.98 yuan per share, with a trading volume of 53.7966 million yuan and a turnover rate of 0.46%, resulting in a total market capitalization of 17.005 billion yuan [1]. - The stock has experienced a net inflow of main funds amounting to 5.0723 million yuan, with significant buying and selling activity from large orders [1].

10月10日，特朗普在社交平台表示，美国将自11月1日起对中国商品征收额外的100%关税，并对关键软 件实施出口管制。特朗普的推文同时引发全球大类资产波动，股债汇齐跌。 不过，在经历了4月份"对等关税"冲击之后，市场已形成了学习效应，不少观点判断这大概率又是一次 典型的"TACO交易"。所谓"TACO交易"，是华尔街流行的面对特朗普政府关税威胁的策略，指的是在 特朗普的关税威胁导致市场下跌时，投资者便押注他最终会退缩，股市将反弹，投资者通过逢低买入而 获利。 今日早盘，三大指数均低开，随后跌幅收窄，截至午间，沪指跌1.3%，深成指跌2.56%，创业板指跌 3%。从早盘表现来看，虽然市场出现一定幅度的震荡，但并未复制4月7日的暴跌行情（沪指跌7.34%、 深成指跌9.66%、创业板指跌12.5%）。 板块方面，金属新材料、贵金属、军工装备等涨幅居前，九菱科技（920505.BJ）最高涨幅超24%，银 河磁体（300127.SZ）、新莱福（301323.SZ）20cm涨停；安泰科技（000969.SZ）、包钢股份 （600010.SH）亦涨停，奔朗新材（920807.BJ）、西磁科技（920061.BJ）等跟涨。 ...

Group 1: Market Reaction to Tariff Announcements - The A-share market showed expected performance with initial declines, but did not replicate the significant drop seen on April 7, where the Shanghai Composite Index fell by 7.34% [1] - Major indices opened lower but narrowed losses by midday, with the Shanghai Composite down 1.3%, Shenzhen Component down 2.56%, and ChiNext down 3% [1] - The market has developed a learning effect from previous tariff announcements, leading to speculation that this could be another typical "TACO trade" scenario, where investors bet on a market rebound following initial declines [1][3] Group 2: Sector Performance - Sectors such as new materials, precious metals, and military equipment saw significant gains, with Jiuling Technology rising over 24% and several other stocks hitting the daily limit [2] - Despite the gains in certain sectors, some investors expressed concerns about the overall risks in the A-share market that need further observation [2] Group 3: Company Responses to Tariff Changes - Companies like Xiangxin Home (匠心家居) are actively monitoring and interpreting the new tariff policies, indicating a proactive approach to adapt to changes [6] - Rui Ming Technology (锐明技术) reported that its revenue from the U.S. market is decreasing, and its new manufacturing center in Vietnam will help mitigate tariff impacts [6] - Pharmaceutical companies such as Huadong Medicine (华东医药) and Qizheng Tibetan Medicine (奇正藏药) indicated that the impact of the new tariffs on their businesses is limited due to low export ratios to the U.S. or existing production bases in the U.S. [7] Group 4: Strategic Adjustments by Companies - Companies have developed comprehensive strategies to cope with trade tensions, including diversifying production locations and reducing reliance on the U.S. market [7][8] - Guan Sheng Co. (冠盛股份) mentioned that its Malaysian factory is exporting products to North America, despite higher costs compared to domestic production, indicating a strategic shift to maintain competitiveness [8]

Core Viewpoint - The transaction between Fangsheng Pharmaceutical and Yifan Pharmaceutical involves the acquisition of the marketing authorization for "Compound Dexamethasone Acetate Cream," which is expected to enhance the company's product portfolio in dermatology and potentially serve as a new profit growth point [1] Group 1: Transaction Details - The contract was signed on September 30, 2025, and does not constitute a related party transaction or a major asset restructuring, falling within the chairman's approval authority [1] - The payment for the transaction will be made in three phases, indicating a structured financial approach to the acquisition [1] Group 2: Market Context - The drug is used for various skin diseases, with 103 companies in China holding production licenses for it [1] - In the first half of 2025, the sales revenue from physical pharmacies for this drug reached 175 million yuan, highlighting its market potential [1] Group 3: Strategic Implications - The acquisition aligns with the company's development strategy to expand its dermatological product offerings, which is expected to contribute positively to future revenue streams [1] - However, the timeline for completing the holder change procedures remains uncertain, and sales may be influenced by market factors, necessitating cautious decision-making by investors [1]

Group 1: Economic Transformation and Development - Hefei has transformed from an inland city with no natural resources into a "net celebrity city" by focusing on technology and industrial upgrades, showcasing a strong development momentum [1] - The city has achieved a GDP growth that has crossed seven trillion yuan milestones, entering the "trillion club" and becoming one of the most popular cities for young people in the Yangtze River Delta [6] Group 2: Low-altitude Economy - Hefei is a pioneer in the low-altitude economy, with over 300 companies in the sector and more than 200 operational routes for drone logistics and urban air transport [3] - The city plans to build over 30 eVTOL takeoff and landing points within three years, creating a comprehensive urban air transport network [3] - The low-altitude economy in Anhui is projected to reach approximately 55 billion yuan by 2024, supported by a 1 billion yuan industrial fund [3] Group 3: Smart Manufacturing - Hefei emphasizes smart manufacturing as a key direction for industrial transformation, leveraging its advantages in scale and comprehensive industrial systems [4] - Lenovo's manufacturing base in Hefei has become a global hub, achieving an industrial output value of 105.7 billion yuan last year [5] - The city has seen a significant increase in new energy vehicle production, with over 1.35 million units produced last year, marking an 81% growth [5] Group 4: Investment and Innovation - Hefei has developed a unique "investment-driven" model to attract social capital for technological innovation and industrial development, exemplified by investments in projects like BOE and NIO [7] - The city is focusing on quantum industries, with nearly 70 companies in the quantum supply chain and significant achievements in quantum communication and computing [8] - Hefei ranks second globally in the quantum information field, showcasing its strength in both research and industrial development [8]